Why Does Testosterone Increase Hematocrit?

Testosterone raises hematocrit by pushing the body to produce more red blood cells through at least two distinct biological pathways: boosting the hormone erythropoietin (EPO), which signals the bone marrow to ramp up red cell production, and suppressing hepcidin, a liver protein that normally limits how much iron is available for building those cells. The effect is dose-dependent and more pronounced in some people than others, with factors like age, body composition, and the type of testosterone formulation all influencing how high hematocrit climbs.

Two Pathways Working in Parallel

The most well-studied mechanism is straightforward: testosterone stimulates the kidneys to release more EPO, which then tells the bone marrow to churn out additional red blood cells. This has been known since at least the mid-twentieth century, when doctors first noticed that men given androgens for various medical conditions developed higher red cell counts. But the picture has become more detailed in recent decades.

Research in hypogonadal men has shown that the roughly 7 to 10 percent increase in hemoglobin and hematocrit seen with testosterone treatment comes alongside a measurable rise in EPO levels, often detectable within the first month.¹ The researchers behind that finding proposed something interesting: testosterone doesn’t just crank up EPO temporarily. It recalibrates the body’s internal thermostat for how much EPO it thinks is appropriate at a given hemoglobin level. In other words, the body resets what it considers “normal” for red cell production.

The second pathway involves hepcidin, a hormone produced by the liver that acts as a gatekeeper for iron. When hepcidin levels are high, iron gets locked away in storage and can’t be used to build new red blood cells. Testosterone suppresses hepcidin, and the suppression is dose-dependent: higher testosterone doses produce bigger drops in hepcidin, which frees up more iron for red cell manufacturing.² In one study, hepcidin dropped markedly within a single week of testosterone administration, and hepcidin levels at four and eight weeks predicted how much hematocrit eventually rose.

These two pathways reinforce each other. EPO tells the marrow to produce more red cells, while hepcidin suppression ensures the raw material (iron) is available to build them. Even during conditions of severe caloric restriction, testosterone maintained this iron-mobilizing effect, suppressing hepcidin by about 41% compared to placebo and keeping red cell production going when it might otherwise have slowed.³ Animal research has confirmed that testosterone’s effects on red cell production are iron-dependent, meaning they partially depend on having iron stores to mobilize in the first place.⁴

Not Through Estrogen, and Not Mainly Through Bone Marrow Cells Directly

Testosterone can be converted into estrogen inside the body through a process called aromatization, so an obvious question is whether the red-cell-boosting effect actually comes from the estrogen, not the testosterone itself. Research in men who genetically lack the enzyme for this conversion answered that question clearly: their hemoglobin, hematocrit, and red cell counts rose with testosterone treatment but failed to increase with estrogen treatment. Testosterone alone was sufficient. Estrogen was not.⁵

Another common assumption is that testosterone works by directly stimulating blood-forming cells in the bone marrow. The reality is more nuanced. Lab studies have found that androgens’ direct survival-enhancing or growth-stimulating effects on blood progenitor cells are minimal and mostly limited to mature red cell precursors. The bigger contribution comes from testosterone’s influence on the surrounding bone marrow environment and on distant organs like the kidneys (via EPO) and liver (via hepcidin).⁶ Mouse studies confirm this pattern: the red cell response to androgens depends on the androgen receptor in non-blood-forming cells, and it works through EPO and downstream iron-regulating signals rather than through direct marrow stimulation.⁷

The Early Phase Is Not What You Think

If you start testosterone therapy and see your hematocrit rise within the first few weeks, it’s tempting to assume the body has already produced a flood of new red blood cells. Early data suggest something different. In a study of men given testosterone enanthate, the initial rise in hematocrit during the first five weeks was attributed to hemoconcentration, a shift in plasma volume rather than actual new red cell production. True red blood cell mass didn’t measurably increase until about the tenth week.⁸

This two-phase pattern matters clinically. An early hematocrit bump could partly reflect a decrease in plasma volume, which concentrates the existing red cells. The later, sustained rise reflects genuinely increased red cell production. A separate study of hypogonadal men on injectable testosterone found a statistically significant increase in whole-body hematocrit and red blood cell volume, with a small but non-significant decrease in plasma volume.⁹ So both mechanisms contribute, but over time the dominant driver is real expansion of red cell mass.

Why the Dose, Your Age, and the Formulation All Matter

The rise in hematocrit with testosterone is dose-dependent in a strikingly linear way. Graded-dose studies in healthy men have shown that higher testosterone doses produce proportionally greater increases in hemoglobin and hematocrit, and the effect is consistently more pronounced in older men than younger ones.¹⁰ The age difference appears to be at least partly explained by the hepcidin pathway: older men showed more dramatic hepcidin suppression in response to testosterone, which corresponded to a bigger hemoglobin rise.²

How testosterone is delivered to the body also changes the picture. A systematic review and network meta-analysis of randomized trials found that intramuscular testosterone cypionate and enanthate (the classic injections) raised hematocrit significantly more than testosterone patches. No significant differences emerged among most other formulations.¹¹ The HEAT Registry, a real-world comparison of testosterone gel versus long-acting intramuscular testosterone undecanoate, put numbers on this disparity: about 23% of men on injections developed a hematocrit above 50%, compared to roughly 5% of men on gel.¹²

The reason likely involves pharmacokinetics. Injections produce a spike in blood testosterone levels followed by a trough, while gels and patches deliver a steadier, lower concentration. That periodic supraphysiologic peak after each injection may drive hepcidin down and EPO up more aggressively than a steady drip of hormone through the skin. In a large cohort study of transgender men, long-acting undecanoate injections carried nearly three times the odds of pushing hematocrit above 50% compared to gel, while short-acting ester injections and oral testosterone did not significantly differ from gel.¹³

Factors That Push Hematocrit Even Higher

Testosterone therapy doesn’t exist in a vacuum. Several coexisting conditions can amplify the hematocrit rise, sometimes pushing it into ranges that concern clinicians.

Obstructive sleep apnea stands out. People with OSA experience repeated drops in blood oxygen during the night, which independently stimulates EPO release. When you add testosterone’s own EPO-boosting and hepcidin-suppressing effects on top of that, the result can be more red cell production than either factor alone would cause. In a study of hypogonadal men on testosterone replacement, those with a diagnosis of OSA had roughly twice the odds of developing polycythemia compared to those without, even after adjusting for age, body mass index, and peak testosterone levels.¹⁴ Making things worse, testosterone itself can sometimes trigger or worsen sleep apnea in susceptible men, creating a vicious cycle. Early case reports documented men developing obstructive sleep apnea and seeing large hematocrit increases after starting testosterone.¹⁵

Smoking is another amplifier. Tobacco use carried about 2.2 times the odds of elevated hematocrit in transgender men on testosterone, likely because carbon monoxide from smoking reduces the oxygen-carrying capacity of existing red cells, prompting the body to make even more.¹⁶ Higher body mass index was also an independent risk factor in that study, with an odds ratio of 3.7 for elevated hematocrit. Pulmonary conditions associated with chronic low oxygen levels showed a similar pattern.

Genetics play a role too. The androgen receptor gene contains a stretch of DNA called the CAG repeat region, and its length varies between individuals. Shorter CAG repeats make the androgen receptor more sensitive to testosterone. In men on long-term intramuscular testosterone undecanoate, shorter CAG repeat lengths predicted a greater chance of hematocrit climbing above 50%.¹⁷ This means two men on the same dose of testosterone can have meaningfully different hematocrit responses based on how sensitive their androgen receptors happen to be.

When Higher Hematocrit Becomes a Health Concern

A modest rise in hematocrit is expected and usually harmless. The concern starts when hematocrit crosses into territory where blood viscosity increases enough to theoretically raise the risk of clots, heart attacks, and strokes. Clinical guidelines commonly flag a hematocrit above 54% as the threshold requiring intervention, though some clinicians begin paying closer attention at 50% or 52%.

The reported incidence of polycythemia in men on testosterone replacement therapy (typically defined as hemoglobin above 18 g/dL or hematocrit above 54%) ranges widely, from about 2.5% to 40% depending on the population studied and the definition used.¹⁸ Much of the variation comes from differences in testosterone dose, formulation, and patient characteristics.

The theoretical danger of a very high hematocrit is that thicker blood flows more slowly and is more prone to clotting. A review of the evidence found that the concern centers on potential increased risk for venous thromboembolism, heart attack, and stroke, though the authors noted that direct evidence linking testosterone therapy to these vascular complications remains limited.¹⁹ The risk picture changes dramatically with anabolic steroid abuse, where weekly doses can reach a gram or more (far beyond therapeutic replacement), sometimes stacked with other drugs like EPO or growth hormone. Small observational studies in that population have documented rates of clotting events, acute coronary syndromes, and sudden cardiac death exceeding what would normally be expected.²⁰

When hematocrit does climb too high, the most common short-term fix is therapeutic phlebotomy, which is essentially having blood drawn to reduce red cell volume. This buys time while the testosterone dose is adjusted or the formulation is switched to one that produces a steadier blood level. Switching from injections to a gel, lowering the injection dose, or increasing the interval between injections are all strategies clinicians use to keep hematocrit within a safer range.

The Long-Term Trajectory in Trans Men

Transgender men on testosterone therapy offer one of the best windows into what happens to hematocrit over years and decades, because they start from a female-range baseline and then experience male-range testosterone levels indefinitely. A large follow-up study tracked hematocrit over up to twenty years and found a characteristic pattern: hematocrit rose most sharply in the first year, jumping from a baseline average of 0.39 to 0.45 L/L. After that, the pace of increase slowed considerably, but the cumulative probability of developing erythrocytosis kept climbing, reaching about 10% after one year and 38% after ten years.¹³

A systematic review covering transgender individuals confirmed that all testosterone formulations result in hematocrit increases regardless of dose, formulation, or method of administration.²¹ There’s no way to take testosterone and completely avoid a rise in red cell production. The question is always about magnitude and management.

The risk factors in this population mirror those in cisgender men on testosterone replacement: older age at the start of therapy, higher BMI, tobacco use, pulmonary conditions, and injectable formulations all independently predicted higher hematocrit.¹⁶ The practical takeaway for trans men is that hematocrit monitoring should not be limited to the first year. Given the slow but steady creep upward over a decade or more, regular blood work remains important for the duration of therapy.

Why Boys Develop Higher Hemoglobin During Puberty

The connection between testosterone and red blood cells is not just a pharmaceutical side effect. It’s the reason adult men have higher hemoglobin and hematocrit than adult women in the first place. A study tracking adolescents through puberty quantified this neatly: hemoglobin concentration stayed essentially flat in girls as they matured but rose about 11% in boys. Total hemoglobin mass (the absolute amount of hemoglobin in the body) increased 33% during female puberty, driven largely by growing body size, but surged 95% in boys.²²

The researchers estimated that direct testosterone effects on red cell production accounted for a meaningful portion of this gap, roughly 65 grams of additional hemoglobin mass per 1 ng/mL increase in testosterone. Part of it also comes indirectly: testosterone promotes lean body mass, and a bigger, more metabolically active body demands more oxygen delivery and therefore more red blood cells. The same EPO and hepcidin pathways that drive hematocrit up in men on testosterone therapy are the ones doing the heavy lifting during normal male puberty. This is the biological machinery working as intended, not a side effect but a core feature of male physiology. That context helps explain why the body’s response to exogenous testosterone is so consistent and predictable: you are pulling a lever the body already knows how to respond to.

1
PubMed Central. Testosterone Induces Erythrocytosis via Increased Erythropoietin and Suppressed Hepcidin: Evidence for a New Erythropoietin/Hemoglobin Set Point
2
PubMed Central. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis
3
PubMed. Testosterone Administration During Energy Deficit Suppresses Hepcidin and Increases Iron Availability for Erythropoiesis
4
PubMed. The role of iron in mediating testosterone’s effects on erythropoiesis in mice
5
PubMed Central. Testosterone action on erythropoiesis does not require its aromatization to estrogen: Insights from the testosterone and estrogen treatment of two aromatase-deficient men
6
PubMed Central. Direct and indirect effects of androgens on survival of hematopoietic progenitor cells in vitro
7
PubMed. Androgens stimulate erythropoiesis through the DNA-binding activity of the androgen receptor in non-hematopoietic cells
8
JAMA Internal Medicine. Androgens and Human Blood Volume Changes: Comparison in Normal and Various Anemic States
9
PubMed. Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence
10
PubMed Central. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men
11
PubMed. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials
12
PubMed. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men
13
PubMed Central. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years
14
PubMed. Obstructive Sleep Apnea Is Associated With Polycythemia in Hypogonadal Men on Testosterone Replacement Therapy
15
PubMed. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep
16
Oxford Academic. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years
17
The Journal of Clinical Endocrinology & Metabolism. Androgen Receptor Gene CAG Repeat Length and Body Mass Index Modulate the Safety of Long-Term Intramuscular Testosterone Undecanoate Therapy in Hypogonadal Men
18
Oxford Academic. Therapeutic Phlebotomy for Testosterone-Induced Polycythemia: A Blood Center’s Perspective
19
PubMed Central. Erythrocytosis Following Testosterone Therapy
20
Research and Practice in Thrombosis and Haemostasis. Thrombotic complications of glucocorticoids and anabolic steroids
21
PubMed. Effect of testosterone formulations on hematocrit in transgender individuals: A systematic review
22
PubMed. Quantification of testosterone-dependent erythropoiesis during male puberty